Safety Profiles of Newer Contraceptives presented at meeting of Society of Reproductive Investigation

RSI Chief Medical Officer, Dr. Donald R. Mattison, in collaboration with colleagues from the Institute for Safe Medication Practices and Wake Forest University, evaluated and compared the safety profiles of newer contraceptives using 43,324 adverse event case reports submitted to the Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS), for the two years ending July 2017.  The presentation on Saturday, March 10, 2018 in San Diego described the strong safety profiles of the newer contraceptives, as well as issues of concern.

For more details see the presentation poster here.

 

Posted in

More RSI News

Evidence-based Risk Assessment Framework

December 12, 2022
Preliminary evidence-based risk assessment framework

Working with international thought leaders in risk science, Risk Sciences International investigators contributed to the development of the evidenced-based risk assessment framework shown in the…

Read News Item

Food safety assessments

November 17, 2022
Problem-formulation-food-safety-assessments

Problem Formulation in Food Safety Assessments conducted by the European Food Safety Authority RSI investigators recently provided advise to the European Food Safety Authority (EFSA)…

Read News Item

Value of information analysis framework

October 28, 2022
VOI paper in Risk Analysis

In its 2007 report on Toxicity Testing in the 21st Century: A Vision and a Strategy, the US National Research Council  (NRC) highlighted need for more rapid…

Read News Item

Principles of risk decision-making

August 19, 2022
RSI logo in white

RSI investigators propose fundamental principles of risk decision-making, and explore their application in a range of real-world risk decision-making contexts. These ten principles will provide valuable guidance on addressing current and future risk issues facing civil societies worldwide.

Read News Item